Methods of using activin receptor type ii signaling inhibitors
Номер патента: EP4359075A2
Опубликовано: 01-05-2024
Автор(ы): Christopher R. Rovaldi, Elissa FURUTANI, Jasbir S. Seehra, Jennifer Lachey
Принадлежит: Keros Therapeutics Inc
Опубликовано: 01-05-2024
Автор(ы): Christopher R. Rovaldi, Elissa FURUTANI, Jasbir S. Seehra, Jennifer Lachey
Принадлежит: Keros Therapeutics Inc
Реферат: The invention features methods of treating a subject having a cytopenia associated with a myelodysplastic syndrome, a cytopenia associated with chronic myelomonocytic leukemia, or a cytopenia associated with myelofibrosis, such as anemia, thrombocytopenia, or neutropenia, by administering to the subject an ActRII signaling inhibitor, such as an ActRIIA ligand trap including an extracellular ActRIIA variant. The extracellular ActRIIA variant may be fused to an Fc domain or moiety.
Methods of using activin receptor type ii signaling inhibitors
Номер патента: WO2022271716A3. Автор: Jasbir S. Seehra,Jennifer Lachey,Christopher R. Rovaldi,Elissa FURUTANI. Владелец: Keros Therapeutics, Inc.. Дата публикации: 2023-03-02.